palbociclib,letrozole
pfizer
['breast', 'ibrance', 'paloma-2']
paloma-2 shows ibrance did not increase survival in hr+/her2- #metastaticbreastcancer, but key questions remain about differences between the three cdk inhibitors. learn more in our coverage of #asco22: 
The mission of Living Beyond Breast Cancer (LBBC) is to connect people with trusted breast cancer information and a community of support.